Management of chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a primary cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.
• Transmission predominantly occurs via percutaneous exposure, often linked to injection drug use.
• Chronic HCV develops in a significant majority of infected individuals.

Purpose of the Study:

• To outline the diagnostic and prognostic significance of HCV antibody screening, viraemia assessment, and genotyping.
• To detail the role of liver biopsy in evaluating hepatic fibrosis and guiding treatment selection.
• To describe the standard of care for antiviral therapy in chronic HCV.

Main Methods:

• Initial screening using HCV antibody detection in at-risk populations.
• Confirmation of chronic infection through assessment of HCV viraemia.
• HCV genotyping to predict treatment response.
• Liver biopsy for fibrosis staging and assessment of concurrent liver conditions.
• Clinical decision-making for antiviral therapy based on disease severity, patient factors, and genotype.

Main Results:

• HCV antibody testing identifies individuals requiring further evaluation.
• HCV viraemia confirms the presence of active infection.
• HCV genotype is a key predictor of treatment efficacy.
• Liver biopsy provides crucial information for patient management and treatment selection.

Conclusions:

• A multi-step diagnostic approach including antibody testing, viraemia assessment, and genotyping is essential for managing HCV.
• Liver biopsy plays a vital role in disease staging and treatment planning.
• Combination therapy with pegylated interferon and ribavirin remains the standard of care for chronic HCV.